Crossmark

Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients

Published Online: 2021-02-25

Published Print: 2021-04

Authors

Liu, Jieqiong

Li, Ying

Li, Qian

Liang, Dandan

Wang, Quanren

Liu, Qiang https://orcid.org/0000-0002-5451-4862
Funding

Funding for this research was provided by:

Natural Science Foundation of China Grant (81630074)

Natural Science Foundation of China Grant (81872141)

Guangzhou Science and Technology Plan Key Projects (201804020076)

Fundamental Research Funds for the Central Universities (20ykpy101)
License Information

Text and Data Mining valid from 2021-02-25

Version of Record valid from 2021-02-25
More Information

Article History

Received: 23 October 2020

Accepted: 3 February 2021

First Online: 25 February 2021

Compliance with ethical standards

:

: The authors declare no conflicts of interest.

: This research was approved by the Clinical Research Ethics Committee of Sun Yat-sen Memorial Hospital of Sun Yat-sen University. And all the studies were performed in accordance with the International Ethical Guidelines for Biomedical Research Involving Human Subjects (CIOMS).

: Written informed consents were obtained from the participants before sampling.

Document is current